Gene Regulation and Therapeutics for Cancer
Gene Regulation and Therapeutics for Cancer
Palanimuthu Ponnusamy, Moorthy; Batra, Surinder K.
Taylor & Francis Ltd
09/2022
322
Mole
Inglês
9780367541163
15 a 20 dias
603
Descrição não disponível.
Programmed Death 1 Receptor (PD-1)-mediated Immunomodulatory Effects in Pancreatic Cancer. Nuclear Factor Kappa-B: Bridging Inflammation and Cancer. The S100A7/8/9 Proteins: Novel Biomarker and Therapeutic Targets for Solid Tumor Stroma. Nuclear Receptor Coactivators: Mechanism and Therapeutic Targeting In Cancer. Liquid Biopsies for Pancreatic Cancer: A Step Towards Early Detection. Targeting Subgroup-specific Cancer Epitopes for Effective Treatment of Pediatric Medulloblastoma. Aberrant Methylation of UC Promoters in Human Pancreatic Ductal Carcinomas. Receptor Tyrosine Kinase Signaling Pathways as a Goldmine for Targeted Therapy in Head and Neck Cancers. Molecular Drivers in Lung Adenocarcinoma: Therapeutic Implications. Molecular Mediator of Prostate Cancer Progression and Its Implication in Therapy. Therapeutic Options for Prostate Cancer: A Contemporary Update. Regulation and Targeting of MUCINS in Pancreatic Cancer. Targeted Therapy for Cancer Stem Cells.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
MUC4 Promoter;Gene Regulation;DNA Origami;Gene Therapy;PDAC Patient;Therapeutics;EGFR TKIs;Gene and disease;PD L1 Expression;definitive oncogenic drivers;EGFR Inhibitor;transcriptional dysregulation;CSCs;targeted cancer therapeutics;TMPRSS2 Erg Fusion;differential gene regulation;DNA Methylation;EGFR TKI;DNA Methylation Status;PD L1 Axis;HNSCC Tumor;HNSCC Patient;NSCLC Patient;PD-1 Expression;PDAC Microenvironment;Nuclear Receptor Co-activator;NF ?B Activation;PD L1 Immunotherapy;PD L1 Antibody;Target CSCs;PARP Inhibitor;PD L1 Therapy;EGFR Mutation
Programmed Death 1 Receptor (PD-1)-mediated Immunomodulatory Effects in Pancreatic Cancer. Nuclear Factor Kappa-B: Bridging Inflammation and Cancer. The S100A7/8/9 Proteins: Novel Biomarker and Therapeutic Targets for Solid Tumor Stroma. Nuclear Receptor Coactivators: Mechanism and Therapeutic Targeting In Cancer. Liquid Biopsies for Pancreatic Cancer: A Step Towards Early Detection. Targeting Subgroup-specific Cancer Epitopes for Effective Treatment of Pediatric Medulloblastoma. Aberrant Methylation of UC Promoters in Human Pancreatic Ductal Carcinomas. Receptor Tyrosine Kinase Signaling Pathways as a Goldmine for Targeted Therapy in Head and Neck Cancers. Molecular Drivers in Lung Adenocarcinoma: Therapeutic Implications. Molecular Mediator of Prostate Cancer Progression and Its Implication in Therapy. Therapeutic Options for Prostate Cancer: A Contemporary Update. Regulation and Targeting of MUCINS in Pancreatic Cancer. Targeted Therapy for Cancer Stem Cells.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
MUC4 Promoter;Gene Regulation;DNA Origami;Gene Therapy;PDAC Patient;Therapeutics;EGFR TKIs;Gene and disease;PD L1 Expression;definitive oncogenic drivers;EGFR Inhibitor;transcriptional dysregulation;CSCs;targeted cancer therapeutics;TMPRSS2 Erg Fusion;differential gene regulation;DNA Methylation;EGFR TKI;DNA Methylation Status;PD L1 Axis;HNSCC Tumor;HNSCC Patient;NSCLC Patient;PD-1 Expression;PDAC Microenvironment;Nuclear Receptor Co-activator;NF ?B Activation;PD L1 Immunotherapy;PD L1 Antibody;Target CSCs;PARP Inhibitor;PD L1 Therapy;EGFR Mutation